Feature ElongationNCT04224298
Preliminary Study on Eye Features of Patients With Malignant Tumors
An observational study of Feature Elongation and Cancer Patients, run by Peking University Cancer Hospital & Institute at 1 site in China.
Trial summary
Based on the theory of traditional Chinese Medicine, this study collects eye features of white eyes through the White Eye Imaging Health Care System under visible light and establishes a database of eye-eye features corresponding to the disease. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Feature Elongation, Cancer Patients
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Feb 2019to 20 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants in the study were patients with malignant tumors and healthy volunteers.
Who may be able to join
- Malignant tumor patients with clear pathological diagnosis;
- Those who have no serious primary diseases of the cardiovascular, cerebrovascular, respiratory, endocrine, urinary, blood and other systems;
- The main organs (hematopoiesis, heart, lung, liver, and kidney) have no obvious abnormal function; ④Age ≥18 years old, ≤75 years old; ⑤ No serious eye disease;
- The patient volunteered to participate in this study.
Who cannot join
- Patients with severe blood loss (because when the bleeding exceeds 300ml, the white eye color of the patient is often pale white);
- Poor patient compliance; ③ pregnant and lactating women;
- Can't cooperate with inspection properly; ⑤ Cannot read or understand the scale.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Application of White Eye Imaging Health Care System on Diagnosis of Malignant Tumors
Based on the theory of traditional Chinese Medicine, this study collects eye features of white eyes through the White Eye Imaging Health Care System under visible light and establishes a database of eye-eye features corresponding to the disease. The computer image analysis and artificial intelligence technology are used to visualize the eye. The features were extracted and classified, and the corresponding changes in the characteristics of the traditional Chinese medicine and the disease were analyzed statistically to establish an analytical model corresponding to the disease.
Read the detailed description
- Collecting the white-eyed eye features of 500 patients with malignant tumors and 500 non-tumor patients by the white-eye shadowless imaging acquisition system under visible light, and establishing eye-catching images of malignant tumor patients and healthy people of different diseases. Feature database.
- Based on the collected four-dimensional eye-eye diagram, using computer image analysis and artificial intelligence technology to extract and classify the eye-eye features of the white eye, and statistically analyze the correlation between the eye-eye features and the malignant tumor. The relationship between the characteristics of the white eye and the corresponding change of malignant tumor.
- Conditions
- Feature Elongation, Cancer Patients
- Keywords
- Eye, Manifestations, Cancer
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Model of white-eye ocular features in patients with malignant tumors
The test will use Artificial Intelligence technology to analyze and learn the features of white-eye eyes of healthy people and patients with malignant tumors, and establish a model of eye characteristics of malignant tumors.
Measured: 2.5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2020
- Study start1 Feb 2019
- Primary completion20 Sep 2022
- Study completion20 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Feature ElongationStudies of the same condition, open and under way.
- More trials run by Peking University Cancer Hospital & InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Xue Dong, Peking University Cancer Hospital & Institute
- Investigators
- Dong D Xue, Principal investigator, Peking University Cancer Hospital & Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04224298
- Sponsor's protocol ID
- WEIS
- Status last verified
- Apr 2024
- First submitted
- 8 Jan 2020
- Last updated
- 9 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This research is still in the exploratory stage and there are no plans to share IPD
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Application of White Eye Imaging Health Care System on Diagnosis of Malignant Tumors
- ClinicalTrials.gov ID
- NCT04224298
- Acronym / sponsor ID
- WEIS
- Conditions
- Feature Elongation, Cancer Patients
- Keywords
- Eye, Manifestations, Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Peking University Cancer Hospital & InstituteUniversity, hospital or other
- Study start
- 1 Feb 2019 (actual)
- Primary completion
- 20 Sep 2022 (actual)
- Study completion
- 20 Sep 2022 (actual)
- First posted
- 13 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Based on the theory of traditional Chinese Medicine, this study collects eye features of white eyes through the White Eye Imaging Health Care System under visible light and establishes a database of eye-eye features corresponding to the disease. The computer image analysis and artificial intelligence technology are used to visualize the eye. The features were extracted and classified, and the corresponding changes in the characteristics of the traditional Chinese medicine and the disease were analyzed statistically to establish an analytical model corresponding to the disease.
Detailed description
- Collecting the white-eyed eye features of 500 patients with malignant tumors and 500 non-tumor patients by the white-eye shadowless imaging acquisition system under visible light, and establishing eye-catching images of malignant tumor patients and healthy people of different diseases. Feature database.
- Based on the collected four-dimensional eye-eye diagram, using computer image analysis and artificial intelligence technology to extract and classify the eye-eye features of the white eye, and statistically analyze the correlation between the eye-eye features and the malignant tumor. The relationship between the characteristics of the white eye and the corresponding change of malignant tumor.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants in the study were patients with malignant tumors and healthy volunteers.
Key inclusion criteria (4 listed)
- Malignant tumor patients with clear pathological diagnosis;
Key exclusion criteria (3 listed)
- Patients with severe blood loss (because when the bleeding exceeds 300ml, the white eye color of the patient is often pale white);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Model of white-eye ocular features in patients with malignant tumors
Time frame: 2.5 years
The test will use Artificial Intelligence technology to analyze and learn the features of white-eye eyes of healthy people and patients with malignant tumors, and establish a model of eye characteristics of malignant tumors.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2024.
- Individual participant dataSharing planned: No. This research is still in the exploratory stage and there are no plans to share IPD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dong D Xue principal investigator
Peking University Cancer Hospital & Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Feature Elongation and Cancer Patients, run by Peking University Cancer Hospital & Institute at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Model of white-eye ocular features in patients with malignant tumors (time frame: 2.5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2024.